Trial Outcomes & Findings for Treatment Pattern of Oral Anticoagulants (OAC) in Japan (NCT NCT02982863)
NCT ID: NCT02982863
Last Updated: 2018-09-14
Results Overview
Number of patients prescribed OAC drug Warfarin at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Recruitment status
COMPLETED
Target enrollment
48696 participants
Primary outcome timeframe
Day 1
Results posted on
2018-09-14
Participant Flow
A retrospective, observational study using health insurance claims data.48696 patients were prescribed dabigatran, warfarin, apixaban, edoxaban, or rivaroxaban as the first OACs but 50 patients were removed as they took more than one these drugs. Thus only 48646 patients were prescribed the drugs of interest.
The Japanese patients diagnosed as Non-Valvular Atrial Fibrillation (NVAF) between April 2010 and June 2016, were prescribed dabigatran, warfarin, apixaban, edoxaban, or rivaroxaban as the first OACs. DPC; Diagnosis Procedure Combination (DPC)
Participant milestones
| Measure |
Dabigatran
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
5745
|
16745
|
13238
|
10158
|
2760
|
|
Overall Study
COMPLETED
|
4936
|
12484
|
11386
|
8758
|
2268
|
|
Overall Study
NOT COMPLETED
|
809
|
4261
|
1852
|
1400
|
492
|
Reasons for withdrawal
| Measure |
Dabigatran
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Overall Study
Not eligible patients
|
809
|
4261
|
1852
|
1400
|
492
|
Baseline Characteristics
Treatment Pattern of Oral Anticoagulants (OAC) in Japan
Baseline characteristics by cohort
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Total
n=39832 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
72 Years
STANDARD_DEVIATION 10 • n=99 Participants
|
78 Years
STANDARD_DEVIATION 10 • n=107 Participants
|
77 Years
STANDARD_DEVIATION 10 • n=206 Participants
|
74 Years
STANDARD_DEVIATION 11 • n=7 Participants
|
77 Years
STANDARD_DEVIATION 10 • n=31 Participants
|
76 Years
STANDARD_DEVIATION 10 • n=30 Participants
|
|
Sex: Female, Male
Female
|
1625 Participants
n=99 Participants
|
5068 Participants
n=107 Participants
|
4737 Participants
n=206 Participants
|
3183 Participants
n=7 Participants
|
1130 Participants
n=31 Participants
|
15743 Participants
n=30 Participants
|
|
Sex: Female, Male
Male
|
3311 Participants
n=99 Participants
|
7416 Participants
n=107 Participants
|
6649 Participants
n=206 Participants
|
5575 Participants
n=7 Participants
|
1138 Participants
n=31 Participants
|
24089 Participants
n=30 Participants
|
PRIMARY outcome
Timeframe: Day 1Population: Patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Number of patients by each type of study-target OAC drug (dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban) prescribed as the first Oral Anticoagulants (OAC) with Non-valvular atrial fibrillation (NVAF)
Outcome measures
| Measure |
Dabigatran
n=5745 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=16745 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=13238 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=10158 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2760 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF
|
4936 Participants
|
12484 Participants
|
11386 Participants
|
8758 Participants
|
2268 Participants
|
PRIMARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Number of patients prescribed OAC drug dabigatran at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
75 milligram (mg)
|
58 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
110 mg
|
164 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
150 mg
|
354 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
220 mg
|
3343 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
225 mg
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
300 mg
|
1072 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
440 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Number of patients prescribed OAC drug Warfarin at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Outcome measures
| Measure |
Dabigatran
n=12484 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.9 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1 mg
|
3125 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.2 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.25 mg
|
62 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.3 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.5 mg
|
630 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.55 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.7 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.75 mg
|
66 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.8 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
1.9 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2 mg
|
4711 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.2 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.25 mg
|
54 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.3 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.4 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.5 mg
|
462 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.7 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
2.75 mg
|
24 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3 mg
|
1913 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3.2 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3.25 mg
|
17 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3.3 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3.5 mg
|
128 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3.7 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
3.75 mg
|
9 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
4 mg
|
421 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
4.25 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
4.5 mg
|
41 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
4.6 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
4.75 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
5 mg
|
468 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
5.5 mg
|
9 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
6 mg
|
25 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
6.5 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
7 mg
|
8 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
7.75 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
8 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
9 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
10 mg
|
16 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
17.5 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
20 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
30 mg
|
12 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
40 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
50 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.002 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.006 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.125 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.2 mg
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.25 mg
|
338 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.3 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.374 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.5 mg
|
1726 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.6 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.625 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.65 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.7 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.75 mg
|
256 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.8 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
0.875 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Number of patients prescribed OAC drug rivaroxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Outcome measures
| Measure |
Dabigatran
n=8758 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
30 mg
|
72 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
5 mg
|
14 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
7.5 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
9.9 mg
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
9.99 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
10 mg
|
4372 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
10.005 mg
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
10.05 mg
|
10 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
10.5 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
15 mg
|
4340 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
20 mg
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
22.5 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Number of patients prescribed OAC drug Apixaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Outcome measures
| Measure |
Dabigatran
n=11386 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
1.25 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
2.5 mg
|
428 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
3.75 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
5 mg
|
6300 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
7.5 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
10 mg
|
4789 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
15 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
20 mg
|
27 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
25 mg
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
35 mg
|
1 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Number of patients prescribed OAC drug edoxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Outcome measures
| Measure |
Dabigatran
n=2268 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Number of Patients Prescribed OAC Drug Edoxaban by Dosage
15 mg
|
279 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Edoxaban by Dosage
30 mg
|
1594 Participants
|
—
|
—
|
—
|
—
|
|
Number of Patients Prescribed OAC Drug Edoxaban by Dosage
60 mg
|
412 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 dayPopulation: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics of patients in each treatment group: age
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: Age
|
72 Years
Standard Deviation 10
|
78 Years
Standard Deviation 10
|
77 Years
Standard Deviation 10
|
74 Years
Standard Deviation 11
|
77 Years
Standard Deviation 10
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics of patients in each treatment group: gender
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: Gender
Female
|
1625 Participants
|
5068 Participants
|
4737 Participants
|
3183 Participants
|
1130 Participants
|
|
Baseline Characteristics: Gender
Male
|
3311 Participants
|
7416 Participants
|
6649 Participants
|
5575 Participants
|
1138 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics of patients in each treatment group: year of initiating treatment
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: Year of Initiating Treatment
2013/3/1-2014/2/28
|
1081 Participants
|
2292 Participants
|
188 Participants
|
1868 Participants
|
29 Participants
|
|
Baseline Characteristics: Year of Initiating Treatment
2011/3/14-2012/2/29
|
404 Participants
|
1138 Participants
|
0 Participants
|
0 Participants
|
8 Participants
|
|
Baseline Characteristics: Year of Initiating Treatment
2012/3/1-2013/2/28
|
1259 Participants
|
2002 Participants
|
0 Participants
|
175 Participants
|
32 Participants
|
|
Baseline Characteristics: Year of Initiating Treatment
2014/3/1-2015/2/28
|
1019 Participants
|
2808 Participants
|
3455 Participants
|
2182 Participants
|
158 Participants
|
|
Baseline Characteristics: Year of Initiating Treatment
2015/3/1-2016/2/29
|
919 Participants
|
3217 Participants
|
5634 Participants
|
3302 Participants
|
1289 Participants
|
|
Baseline Characteristics: Year of Initiating Treatment
2016/3/1-2016/6/30
|
254 Participants
|
1027 Participants
|
2109 Participants
|
1231 Participants
|
752 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics of patients in each treatment group: speciality of prescribers of OAC. int.= internal; Med.= Medicine
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Comprehensive medical care
|
13 Participants
|
56 Participants
|
12 Participants
|
9 Participants
|
3 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Internal medicine
|
1689 Participants
|
4316 Participants
|
3943 Participants
|
2816 Participants
|
654 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Psychiatry
|
9 Participants
|
38 Participants
|
30 Participants
|
20 Participants
|
7 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Neurology
|
0 Participants
|
1 Participants
|
7 Participants
|
3 Participants
|
2 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Respiratory
|
66 Participants
|
180 Participants
|
95 Participants
|
72 Participants
|
17 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Gastroenterology
|
106 Participants
|
283 Participants
|
100 Participants
|
125 Participants
|
26 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Plastic surgery
|
5 Participants
|
21 Participants
|
10 Participants
|
5 Participants
|
2 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Cranial nerve surgery
|
319 Participants
|
668 Participants
|
932 Participants
|
654 Participants
|
164 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Cardiovascular surgery
|
87 Participants
|
405 Participants
|
115 Participants
|
147 Participants
|
54 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Pediatric surgery
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Otorhinolaryngology
|
8 Participants
|
47 Participants
|
25 Participants
|
19 Participants
|
5 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Rehabilitation
|
30 Participants
|
127 Participants
|
86 Participants
|
86 Participants
|
12 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Radiology
|
4 Participants
|
12 Participants
|
8 Participants
|
5 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Neuropathic internal medicine
|
210 Participants
|
410 Participants
|
518 Participants
|
415 Participants
|
74 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Gastrointestinal
|
0 Participants
|
17 Participants
|
5 Participants
|
3 Participants
|
1 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Nephrology
|
13 Participants
|
85 Participants
|
27 Participants
|
15 Participants
|
7 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Hemodialysis
|
1 Participants
|
8 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Endocrinology
|
8 Participants
|
24 Participants
|
16 Participants
|
15 Participants
|
2 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Diabetes medicine
|
4 Participants
|
19 Participants
|
12 Participants
|
9 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Large intestine and proctology
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Connective tissue disease & iheumatic int. med.
|
2 Participants
|
8 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Stroke
|
2 Participants
|
6 Participants
|
5 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Psychiatry & neurology
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Unknown
|
27 Participants
|
59 Participants
|
38 Participants
|
83 Participants
|
8 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Hematology
|
6 Participants
|
27 Participants
|
11 Participants
|
20 Participants
|
2 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Psychodiagnosis medical
|
2 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Cardiology
|
1457 Participants
|
2447 Participants
|
2610 Participants
|
2268 Participants
|
465 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Allergy
|
1 Participants
|
9 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Rheumatology
|
7 Participants
|
11 Participants
|
6 Participants
|
3 Participants
|
2 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Pediatrics
|
0 Participants
|
5 Participants
|
4 Participants
|
4 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Surgery
|
109 Participants
|
514 Participants
|
202 Participants
|
175 Participants
|
52 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Orthopedics
|
113 Participants
|
550 Participants
|
212 Participants
|
178 Participants
|
317 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Thoracic surgery
|
10 Participants
|
58 Participants
|
27 Participants
|
25 Participants
|
3 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Obstetrics and gynecology
|
4 Participants
|
11 Participants
|
9 Participants
|
5 Participants
|
6 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Ophthalmology
|
19 Participants
|
38 Participants
|
26 Participants
|
36 Participants
|
5 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Dermatology
|
9 Participants
|
41 Participants
|
23 Participants
|
23 Participants
|
3 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Urology
|
31 Participants
|
161 Participants
|
76 Participants
|
55 Participants
|
15 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Gynecology
|
2 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Respiratory medicine
|
36 Participants
|
161 Participants
|
112 Participants
|
75 Participants
|
18 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Cardiovascular internal medicine
|
444 Participants
|
1258 Participants
|
1930 Participants
|
1218 Participants
|
301 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Diabetes
|
3 Participants
|
14 Participants
|
8 Participants
|
10 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Metabolism internal medicine
|
0 Participants
|
3 Participants
|
4 Participants
|
7 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Emergency medicine
|
18 Participants
|
59 Participants
|
54 Participants
|
46 Participants
|
11 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Gastroenterological medicine
|
53 Participants
|
270 Participants
|
61 Participants
|
85 Participants
|
20 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Digestive surgery
|
6 Participants
|
25 Participants
|
7 Participants
|
10 Participants
|
4 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Hepato-biliarypancreatic surgery
|
0 Participants
|
4 Participants
|
4 Participants
|
1 Participants
|
1 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Oncotherapy
|
2 Participants
|
6 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Breast and thyroid surgery
|
0 Participants
|
3 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Pediatric cardiology
|
0 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Palliative care
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Hematology & medical Oncology
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Endocrinology & metabolism
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
|
Baseline Characteristics: Speciality of Prescribers of OAC
Anesthesiology
|
0 Participants
|
7 Participants
|
6 Participants
|
4 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics of patients in each treatment group: history of disease and hospitalization.
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: History of Disease
Stroke or transient ischemic attack
|
63 Participants
|
145 Participants
|
128 Participants
|
85 Participants
|
21 Participants
|
|
Baseline Characteristics: History of Disease
Myocardial infarction
|
317 Participants
|
903 Participants
|
890 Participants
|
629 Participants
|
178 Participants
|
|
Baseline Characteristics: History of Disease
Coronary artery disease
|
39 Participants
|
87 Participants
|
79 Participants
|
53 Participants
|
25 Participants
|
|
Baseline Characteristics: History of Disease
Heart failure
|
1899 Participants
|
6750 Participants
|
5099 Participants
|
3580 Participants
|
977 Participants
|
|
Baseline Characteristics: History of Disease
Diabetes mellitus
|
1979 Participants
|
4804 Participants
|
4255 Participants
|
3324 Participants
|
841 Participants
|
|
Baseline Characteristics: History of Disease
Dyslipidemia
|
1366 Participants
|
2888 Participants
|
3109 Participants
|
2402 Participants
|
597 Participants
|
|
Baseline Characteristics: History of Disease
Arterial hypertension
|
2938 Participants
|
8501 Participants
|
6990 Participants
|
5357 Participants
|
1344 Participants
|
|
Baseline Characteristics: History of Disease
Peripheral artery disease
|
580 Participants
|
1538 Participants
|
1290 Participants
|
933 Participants
|
252 Participants
|
|
Baseline Characteristics: History of Disease
Peptic ulcer disease
|
958 Participants
|
2301 Participants
|
2148 Participants
|
1558 Participants
|
452 Participants
|
|
Baseline Characteristics: History of Disease
Dementia
|
107 Participants
|
447 Participants
|
348 Participants
|
268 Participants
|
90 Participants
|
|
Baseline Characteristics: History of Disease
Malignant lymphoma
|
62 Participants
|
171 Participants
|
159 Participants
|
109 Participants
|
41 Participants
|
|
Baseline Characteristics: History of Disease
Leukemia
|
34 Participants
|
161 Participants
|
107 Participants
|
82 Participants
|
27 Participants
|
|
Baseline Characteristics: History of Disease
Solid tumor cancer
|
1501 Participants
|
3830 Participants
|
3413 Participants
|
2524 Participants
|
678 Participants
|
|
Baseline Characteristics: History of Disease
Kidney impairment
|
199 Participants
|
697 Participants
|
527 Participants
|
360 Participants
|
118 Participants
|
|
Baseline Characteristics: History of Disease
Liver disease
|
784 Participants
|
1777 Participants
|
1576 Participants
|
1257 Participants
|
339 Participants
|
|
Baseline Characteristics: History of Disease
Valvular disease
|
1659 Participants
|
4294 Participants
|
2961 Participants
|
2561 Participants
|
615 Participants
|
|
Baseline Characteristics: History of Disease
Bleeding (gastrointestinal, etc.)
|
1619 Participants
|
3867 Participants
|
3567 Participants
|
2677 Participants
|
782 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics: history of hospitalization
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: History of Hospitalization
|
2384 Participants
|
9494 Participants
|
6517 Participants
|
4589 Participants
|
1412 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC.
Baseline characteristics of patients in each treatment group: Atrial Fibrillation (AF) risk score CHADS2: Congestive heart failure, Hypertension, Age, Diabetes, Stroke(doubled). CHADS2 score range from 0-6, with higher scores indicating the higher risk CHA2DS2VASc: Cardiac failure or dysfunction, Hypertension, Age 75 (doubled), Diabetes, Stroke (doubled) Vascular disease, Age 65-74 and Sex category (female) score. CHA2DS2VASc score range from 1-9, with higher scores indicating the higher risk. HAS-BLED: Hypertension, Abnormal renal function, Abnormal hepatic function. HAS-BLED score range from 0-8, with higher scores indicating the higher risk.
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: AF Risk Score
0 (CHADS2)
|
707 Participants
|
750 Participants
|
1150 Participants
|
1072 Participants
|
238 Participants
|
|
Baseline Characteristics: AF Risk Score
1 (CHA2DS2VASc)
|
547 Participants
|
585 Participants
|
773 Participants
|
783 Participants
|
140 Participants
|
|
Baseline Characteristics: AF Risk Score
2 (CHA2DS2VASc)
|
878 Participants
|
1500 Participants
|
1692 Participants
|
1481 Participants
|
305 Participants
|
|
Baseline Characteristics: AF Risk Score
3 (CHA2DS2VASc)
|
968 Participants
|
2380 Participants
|
2213 Participants
|
1735 Participants
|
497 Participants
|
|
Baseline Characteristics: AF Risk Score
4 (CHA2DS2VASc)
|
916 Participants
|
2685 Participants
|
2216 Participants
|
1718 Participants
|
432 Participants
|
|
Baseline Characteristics: AF Risk Score
5 (CHA2DS2VASc)
|
690 Participants
|
2496 Participants
|
2070 Participants
|
1348 Participants
|
380 Participants
|
|
Baseline Characteristics: AF Risk Score
6 (CHA2DS2VASc)
|
441 Participants
|
1482 Participants
|
1165 Participants
|
769 Participants
|
241 Participants
|
|
Baseline Characteristics: AF Risk Score
7 (CHA2DS2VASc)
|
188 Participants
|
738 Participants
|
644 Participants
|
402 Participants
|
129 Participants
|
|
Baseline Characteristics: AF Risk Score
0 (HAS-BLED)
|
297 Participants
|
245 Participants
|
422 Participants
|
432 Participants
|
68 Participants
|
|
Baseline Characteristics: AF Risk Score
5 (HAS-BLED)
|
89 Participants
|
403 Participants
|
266 Participants
|
162 Participants
|
46 Participants
|
|
Baseline Characteristics: AF Risk Score
3 (CHADS2)
|
1053 Participants
|
3458 Participants
|
2787 Participants
|
2005 Participants
|
523 Participants
|
|
Baseline Characteristics: AF Risk Score
4 (CHADS2)
|
582 Participants
|
1897 Participants
|
1611 Participants
|
1014 Participants
|
267 Participants
|
|
Baseline Characteristics: AF Risk Score
5 (CHADS2)
|
243 Participants
|
816 Participants
|
626 Participants
|
459 Participants
|
125 Participants
|
|
Baseline Characteristics: AF Risk Score
6 (CHADS2)
|
117 Participants
|
508 Participants
|
378 Participants
|
258 Participants
|
85 Participants
|
|
Baseline Characteristics: AF Risk Score
1 (CHADS2)
|
1103 Participants
|
2239 Participants
|
2504 Participants
|
1928 Participants
|
513 Participants
|
|
Baseline Characteristics: AF Risk Score
0 (CHA2DS2VASc)
|
198 Participants
|
182 Participants
|
280 Participants
|
295 Participants
|
66 Participants
|
|
Baseline Characteristics: AF Risk Score
2 (CHADS2)
|
1131 Participants
|
2816 Participants
|
2330 Participants
|
2022 Participants
|
517 Participants
|
|
Baseline Characteristics: AF Risk Score
7 (HAS-BLED)
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Baseline Characteristics: AF Risk Score
8 (CHA2DS2VASc)
|
96 Participants
|
369 Participants
|
257 Participants
|
188 Participants
|
61 Participants
|
|
Baseline Characteristics: AF Risk Score
9 (CHA2DS2VASc)
|
14 Participants
|
67 Participants
|
76 Participants
|
39 Participants
|
17 Participants
|
|
Baseline Characteristics: AF Risk Score
1 (HAS-BLED)
|
1276 Participants
|
2303 Participants
|
2848 Participants
|
2228 Participants
|
545 Participants
|
|
Baseline Characteristics: AF Risk Score
2 (HAS-BLED)
|
1616 Participants
|
4180 Participants
|
3725 Participants
|
2884 Participants
|
746 Participants
|
|
Baseline Characteristics: AF Risk Score
3 (HAS-BLED)
|
1192 Participants
|
3738 Participants
|
2837 Participants
|
2159 Participants
|
590 Participants
|
|
Baseline Characteristics: AF Risk Score
4 (HAS-BLED)
|
458 Participants
|
1562 Participants
|
1258 Participants
|
872 Participants
|
270 Participants
|
|
Baseline Characteristics: AF Risk Score
6 (HAS-BLED)
|
7 Participants
|
53 Participants
|
30 Participants
|
20 Participants
|
3 Participants
|
|
Baseline Characteristics: AF Risk Score
8 (HAS-BLED)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC
Baseline characteristics of patients in each treatment group: concomitant medication
Outcome measures
| Measure |
Dabigatran
n=4936 Participants
Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Warfarin
n=12484 Participants
Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Apixaban
n=11386 Participants
Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Rivaroxaban
n=8758 Participants
Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
Edoxaban
n=2268 Participants
Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.
|
|---|---|---|---|---|---|
|
Baseline Characteristics: Concomitant Medication
Aspirin
|
989 Participants
|
2848 Participants
|
2027 Participants
|
1621 Participants
|
377 Participants
|
|
Baseline Characteristics: Concomitant Medication
Ticlodipine
|
69 Participants
|
179 Participants
|
115 Participants
|
95 Participants
|
12 Participants
|
|
Baseline Characteristics: Concomitant Medication
Cilostazole
|
199 Participants
|
522 Participants
|
466 Participants
|
306 Participants
|
66 Participants
|
|
Baseline Characteristics: Concomitant Medication
Clopidogrel
|
346 Participants
|
1049 Participants
|
1031 Participants
|
767 Participants
|
153 Participants
|
|
Baseline Characteristics: Concomitant Medication
ARB or ACE
|
1649 Participants
|
4773 Participants
|
3650 Participants
|
2954 Participants
|
661 Participants
|
|
Baseline Characteristics: Concomitant Medication
Beta blocker
|
1779 Participants
|
4376 Participants
|
4272 Participants
|
3137 Participants
|
768 Participants
|
|
Baseline Characteristics: Concomitant Medication
Amiodarone
|
62 Participants
|
388 Participants
|
301 Participants
|
138 Participants
|
31 Participants
|
|
Baseline Characteristics: Concomitant Medication
Procainamide
|
14 Participants
|
40 Participants
|
43 Participants
|
17 Participants
|
8 Participants
|
|
Baseline Characteristics: Concomitant Medication
Disopyramide
|
102 Participants
|
230 Participants
|
180 Participants
|
150 Participants
|
34 Participants
|
|
Baseline Characteristics: Concomitant Medication
Flecainide
|
130 Participants
|
105 Participants
|
237 Participants
|
150 Participants
|
33 Participants
|
|
Baseline Characteristics: Concomitant Medication
Pilsicainide
|
582 Participants
|
726 Participants
|
970 Participants
|
885 Participants
|
145 Participants
|
|
Baseline Characteristics: Concomitant Medication
Calcium channel blockers (CCB)
|
2176 Participants
|
5755 Participants
|
5148 Participants
|
3955 Participants
|
955 Participants
|
|
Baseline Characteristics: Concomitant Medication
Digoxin
|
506 Participants
|
1959 Participants
|
944 Participants
|
896 Participants
|
134 Participants
|
|
Baseline Characteristics: Concomitant Medication
Diuretics
|
1277 Participants
|
5901 Participants
|
3698 Participants
|
2480 Participants
|
681 Participants
|
|
Baseline Characteristics: Concomitant Medication
Statins
|
1029 Participants
|
2736 Participants
|
2364 Participants
|
1876 Participants
|
407 Participants
|
|
Baseline Characteristics: Concomitant Medication
Proton pump inhibitor
|
1869 Participants
|
5512 Participants
|
4583 Participants
|
3506 Participants
|
970 Participants
|
|
Baseline Characteristics: Concomitant Medication
H2 receptor antagonist
|
761 Participants
|
2559 Participants
|
1673 Participants
|
1365 Participants
|
367 Participants
|
Adverse Events
Dabigatran
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Warfarin
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Apixaban
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Rivaroxaban
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Edoxaban
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Boehringer Ingelheim, Call Center
Boehringer Ingelheim
Phone: 1-800-243-0127
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place